![Ton N. Schumacher](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/ton-n.-schumacher/9431304-2-eng-GB/ton-n.-schumacher_i770.jpg)
Using ex vivo avatars to understand immune reactivation in cancer
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
![Steffen Böttcher](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/steffen-boettcher/9431292-1-eng-GB/steffen-boettcher_i770.jpg)
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
![Johanna Joyce](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/johanna-joyce/9431139-1-eng-GB/johanna-joyce_i770.jpg)
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system